TrialBlood2009

Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.

Carmen Fava et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.